For people with symptomatic disease necessitating therapy, ibrutinib is frequently recommended depending on 4 phase III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and other typically utilised CIT combinations, namely FCR, bendamustine in addition rituximab and chlorambucil in addition obinutuzumab (ClbO).107–